Increased bile acid synthesis and impaired bile acid transport in human obesity

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 5, 2016, Pages 1935-1944

  Haeusler, Rebecca A ^a   Camastra, Stefania ^b   Nannipieri, Monica ^b   Astiarraga, Brenno ^b   Castro Perez, Jose ^c   Xie, Dan ^c   Wang, Liangsu ^c   Chakravarthy, Manu ^c   Ferrannini, Ele ^b,d  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE SALT EXPORT PUMP; FARNESOID X RECEPTOR; INSULIN; SODIUM BILE ACID COTRANSPORTER; STEROID 12ALPHA MONOOXYGENASE; BILE ACID BINDING PROTEINS; CARRIER PROTEIN; MEMBRANE PROTEIN;

ARTICLE; BILE ACID SYNTHESIS; BODY MASS; CLINICAL ARTICLE; COLON; CONTROLLED STUDY; CORRELATIONAL STUDY; DUODENUM; FEMALE; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN TISSUE; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; ILEUM; INSULIN RESISTANCE; INSULIN SENSITIVITY; JEJUNUM; LIPID TRANSPORT; LIVER BIOPSY; MALE; MIXED MEAL TOLERANCE TEST; OBESITY; PANCREAS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADULT; BIOSYNTHESIS; GLUCOSE CLAMP TECHNIQUE; INTESTINE; LIVER; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INTESTINES; LIVER; MALE; MEMBRANE GLYCOPROTEINS; OBESITY; PANCREAS;

EID: 84969872664     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2583     Document Type: Article

References (44)

1. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89:147-191.
2. Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:573-583.
3. Cariou B, Chetiveaux M, Zair Y, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nut Metab. 2011;8:48.
4. Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes. 2013;62:4184-4191.
5. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology. 2010; 52(4):1455-1464.
6. Ferrannini E, Camastra S, Astiarraga B, et al. Increased bile acid synthesis and deconjugation after biliopancreatic diversion. Diabetes 2015;64(10):3377-3385.
7. Wewalka M, Patti ME, Barbato C, Houten SM, Goldfine AB. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab. 2014;99:1442-1451.
8. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83:633-671.
9. Dietschy JM. Mechanisms for the intestinal absorption of bile acids. J Lipid Res. 1968;9:297-309.
10. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology. 2004;126:322-342.
11. Ballatori N, Li N, Fang F, Boyer JL, Christian WV, Hammond CL. OSTα-OSTβ: a key membrane transporter of bile acids and conjugated steroids. Front Biosci (Landmark edition). 2009;14:2829-2844.
12. Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest. 1982;70:724-731.
13. LaRusso NF, Hoffman NE, Korman MG, Hofmann AF, Cowen AE. Determinants of fasting and postprandial serum bile acid levels in healthy man. Am J Digest Dis. 1978;23:385-391.
14. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53:1723-1737.
15. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7:678-693.
16. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12:384-392.
17. Prawitt J, Caron S, Staels B. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol Metab. 2014;25:235-244.
18. Chen L, Yao X, Young A, et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012;302:E68-E76.
19. Wu Y, Aquino CJ, Cowan DJ, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013;56:5094-5114.
20. Bouchi R, Foo KS, Hua H, et al. FOXO1inhibition yields functional insulin-producing cells in human gut organoid cultures. Nat Commun. 2014;5:4242.
21. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 1989;30: 719-730.
22. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16:895-906.
23. Steiner C, Othman A, Saely CH, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One. 2011; 6:e25006.
24. Miettinen TA. Cholesterol production in obesity. Circulation. 1971;44:842-850.
25. Stahlberg D, Rudling M, Angelin B, et al. Hepatic cholesterol metabolism in human obesity. Hepatology. 1997;25:1447-1450.
26. van Berge-Henegouwen GP, Hofmann AF. Systemic spill-over of bile acids. Eur J Clin Invest. 1983;13:433-437.
27. Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology. 2005;129:1445-1453.
28. Kaur A, Patankar JV, de Haan W, et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes. 2014;64(4): 1168-1179.
29. Slatis K, Gafvels M, Kannisto K, et al. Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res. 2010;51:3289-3298.
30. Webster CR, Anwer MS. Role of the PI3K/PKB signaling pathway in cAMP-mediated translocation of rat liver Ntcp. Am J Physiol. 1999;277:G1165-G1172.
31. Webster CR, Srinivasulu U, Ananthanarayanan M, Suchy FJ, Anwer MS. Protein kinase B/Akt mediates cAMP- and cell swelling-stimulatedNa +/taurocholate cotransport and Ntcp translocation. J Biol Chem. 2002;277:28578-28583.
32. Shaham O, Wei R, Wang TJ, et al. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol. 2008;4:214.
33. Zhao X, Peter A, Fritsche J, et al. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab. 2009;296:E384-E393.
34. Meier PJ. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am J Physiol. 1995;269:G801-G812.
35. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes. (Lond). 2013;37(12):1553-1559.
36. Glicksman C, Pournaras DJ, Wright M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem. 2010;47:482-484.
37. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009;50:2340-2357.
38. Vaquero J, Monte MJ, Dominguez M, Muntane J, Marin JJ. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochem Pharmacol. 2013;86:926-939.
39. Boesjes M, Bloks VW, Hageman J, et al. Hepatic farnesoid X-receptor isoforms α2 and α4 differentially modulate bile salt and lipoprotein metabolism in mice. PLoS One. 2014;9:e115028.
40. Jansen PL, Strautnieks SS, Jacquemin E, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology. 1999;117:1370-1379.
41. van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology. 2004;127:379-384.
42. Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology. 2015;61(1):260-267.
43. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol. 2010;26:5-11.
44. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66:948-983.